Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders - DelveInsight | Featuring Grünenthal GmbH, AlgoTherapeutix, Wex Pharmaceuticals Inc

With Chemotherapy Induced Peripheral Neuropathy (CIPN) reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline comprises 4+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Chemotherapy Induced Peripheral Neuropathy (CIPN). These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders, including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Chemotherapy Induced Peripheral Neuropathy (CIPN) Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Chemotherapy Induced Peripheral Neuropathy (CIPN) Drug Development @ https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Report

DelveInsight's Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline report depicts a robust space with 4+ active players working to develop 5+ pipeline therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN) treatment.
In July 2025, July 2025: Asahi Kasei Pharma launched a Phase III trial in Japan for ART-123 (Recomodulin), a recombinant thrombomodulin being tested for CIPN prevention in colorectal cancer patients receiving oxaliplatin6. Earlier studies showed promising safety and efficacy.
In July 2025, Ananda Pharma began a Phase I pharmacokinetic study of MRX1, a -based drug being developed for CIPN and endometriosis. The study supports future FDA submissions
In May 2025, researchers at VCU Massey Cancer Center identified the AEG-1 gene as a key regulator of inflammation in CIPN. Targeting this gene may offer a new therapeutic strategy to prevent nerve damage caused by chemotherapy.
In January 2025, the FDA released draft guidance for developing drugs and biologics to prevent or treat CIPN in oncology patients. This document outlines clinical trial design, endpoints, and regulatory expectations, signaling increased support for innovation in this space.
Key Chemotherapy Induced Peripheral Neuropathy (CIPN) companies such as Capsaicin, ATX01, and others are evaluating new drugs for Chemotherapy Induced Peripheral Neuropathy (CIPN) to improve the treatment landscape.
Promising Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline therapies in various stages of development include P 1037, and others.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Overview:

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and challenging complication associated with cancer treatment-especially with widely used chemotherapy agents. It can develop during therapy and may necessitate dose reductions or early discontinuation, potentially compromising treatment success and patient survival.

While acute CIPN often subsides after chemotherapy ends, some individuals may experience lingering or delayed-onset symptoms that continue well after treatment. The incidence and severity of CIPN can remain elevated for months, influenced by the specific chemotherapy regimen and individual patient characteristics. Despite rising cancer survival rates, CIPN continues to pose significant hurdles for both patients and clinicians due to its impact on everyday life and the lack of consistently effective treatments. Prevention and timely intervention are essential to manage its effects.

Download the Chemotherapy Induced Peripheral Neuropathy (CIPN) sample report to know in detail about the Chemotherapy Induced Peripheral Neuropathy (CIPN) treatment market @ https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Analysis
The Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Chemotherapy Induced Peripheral Neuropathy (CIPN) Market.

Categorizes Chemotherapy Induced Peripheral Neuropathy (CIPN) therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) drugs under development based on:

Stage of development

Chemotherapy Induced Peripheral Neuropathy (CIPN) Route of administration

Target receptor

Monotherapy vs. combination therapy

Chemotherapy Induced Peripheral Neuropathy (CIPN) Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Chemotherapy Induced Peripheral Neuropathy (CIPN) Licensing agreements

Funding and investment activities supporting future Chemotherapy Induced Peripheral Neuropathy (CIPN) market advancement.

Unlock key insights into emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) therapies and market strategies here: https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Chemotherapy Induced Peripheral Neuropathy (CIPN) Emerging Drugs

Capsaicin: Grünenthal GmbH

QUTENZA is a high-concentration topical treatment that delivers prescription-grade capsaicin directly to the skin in a medical setting. This targeted application works by temporarily desensitizing and disabling the TRPV1 receptor, a key player in transmitting pain signals. Through this mechanism, a single localized procedure with QUTENZA can offer long-lasting pain relief-up to three months.

ATX01: AlgoTherapeutix

ATX01 is an investigational topical therapy aimed at alleviating peripheral neuropathic pain, specifically in patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN). It works by inhibiting key nociceptive sodium channels involved in pain signaling pathways, delivering localized relief to affected areas such as the hands and feet, where CIPN-related discomfort is often most severe.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Therapeutic Assessment

Chemotherapy Induced Peripheral Neuropathy (CIPN) Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Chemotherapy Induced Peripheral Neuropathy (CIPN) By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chemotherapy Induced Peripheral Neuropathy (CIPN) Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chemotherapy Induced Peripheral Neuropathy (CIPN) Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) therapies and key Chemotherapy Induced Peripheral Neuropathy (CIPN) companies: https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Chemotherapy Induced Peripheral Neuropathy (CIPN) Current Treatment Patterns
4. Chemotherapy Induced Peripheral Neuropathy (CIPN) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chemotherapy Induced Peripheral Neuropathy (CIPN) Late-Stage Products (Phase-III)
7. Chemotherapy Induced Peripheral Neuropathy (CIPN) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chemotherapy Induced Peripheral Neuropathy (CIPN) Discontinued Products
13. Chemotherapy Induced Peripheral Neuropathy (CIPN) Product Profiles
14. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
15. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Products
16. Dormant and Discontinued Products
17. Chemotherapy Induced Peripheral Neuropathy (CIPN) Unmet Needs
18. Chemotherapy Induced Peripheral Neuropathy (CIPN) Future Perspectives
19. Chemotherapy Induced Peripheral Neuropathy (CIPN) Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline reports offerings: https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.